Suven Life Science has acquired all the shares of Suven Pharmaceuticals (SPL), a public limited company, from its existing shareholders. Pursuant to which, Suven Pharmaceuticals has become a wholly owned subsidiary of the company. The board of directors at their meetings held on February 5, 2019 approved the same. The Board also approved draft Scheme of Arrangement to be filed at the National Company Law Tribunal bench at Hyderabad, for necessary approvals.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets.
